We would like to report on the impact of the ovarian hyperstimulation syndrome (OHSS) on thyroid function. We believe that the effects on thyroid function were due to the high estradiol levels in our patient. A 37-year-old woman with autoimmune hypothyroidism taking 125 mg levothyroxine (LT4) daily who was scheduled to undergo controlled ovarian hyperstimulation (COH) was seen in the outpatient clinic for evaluation of the thyroid function. Serum thyroid-stimulating hormone (TSH) was at the upper limit of normal (3.5 mIU=L; reference value 0.27-4.2), and free thyroxine (FT4) was normal (11.1 ng=L; reference value 9.3-17.2). She was advised to increase her dose of LT4 to 150 mg daily for at least 4 weeks before starting COH. The patient refused and did not follow this recommendation before COH. COH consisted of 6 days orgalutran followed by 8 days of treatment with Menopur 1125 IE, and to trigger ovulation (OI) she received 10,000 U hCG. Unfortunately, she developed grade 2 (moderate) OHSS as determined by previously published diagnostic criteria (1,2). The pertinent features were abdominal discomfort and nausea, and the ultrasound image showed multicystic ovaries with diameters >10 cm and very high E 2 levels of 5.549 ng=L. The patient's pregnancy, based on hCG levels of 360 IU=L, was established 14 days after hCG injection for OI. At that moment, thyroid function tests were performed, revealing a severe but asymptomatic hypothyroidism; serum TSH was 41.5 mIU=L, and FT4 was 7.7 ng=L (Fig. 1) . The patient's LT4 dose was increased to 200 mg daily, and the serum TSH decreased to 3.1 mIU=L 44 days after hCG injection and to 0.1 mIU=L 58 days later. When TSH was 0.1 mIU=L, the serum hCG level was 35,340 IU=L and the serum E2 declined to 1900 ng=L. She delivered a healthy boy to end the pregnancy of normal-term length.
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Adequate thyroid function is required for a normal gonadal function and optimal fertilization (3,4). Therefore, tests for thyroid function and autoimmunity should be performed in the workup of infertile women, and thyroid dysfunction, if discovered, should be appropriately treated. Since COH may increase the demands for thyroid hormone (5,6), we recommend that serum TSH concentrations be in the range of 0.27-2.5 mIU=L by adjusting the thyroid hormone dose in hypothyroid women who are scheduled for COH. The present case illustrates that a high normal TSH in a patient with thyroid autoimmunity (TAI) and hypothyroidism can lead to supranormal TSH levels after COH complicated by OHSS. In a previous study we showed that COH has a greater impact on thyroid function in women with TAI than in women without TAI (7).
In the particular setting of OHSS complicating COH as illustrated in the present case report, the dose increment in thyroid hormones was much higher compared to that in spontaneous pregnancies or in women with uncomplicated COH as described in the paper by Davis et al. (8) . In that paper it is advised that pregnant women treated with LT4 increase their dosage with a mean of 32% after fertility treatment and 30% in spontaneously pregnant women. The authors observed no significant differences in the need to increase LT4 in both groups of women, but postconception TSH levels were clearly higher after COH compared to those in spontaneous pregnant women. The lack of significance may, however, be related to a sampling error. This case report and the study by Davis et al. make it probable that the increment in LT4 is mainly dependent on the duration and the level of increment in E2 levels. Further studies are definitely needed to determine the exact increment in LT4 according to E2 levels.
This case report and the data on the impact of high estrogens on thyroid function add some arguments in favor of lowering the upper TSH limit before COH to anticipate the possible development of clinical hypothyroidism (9,10).
Screening for thyroid disorders is recommended in women with infertility, followed by strict follow-up, when COH is planned and if TAI was initially associated. 
